Hinge Health CFO sells 5,907 shares

Hinge Health, Inc. Chief Financial Officer James Budge reported open-market sales of a total of 5,907 shares of the company’s Class A Common Stock on May 26, 2026.

Rhea-AI Filing Summary

Hinge Health, Inc. Chief Financial Officer James Budge reported open-market sales of a total of 5,907 shares of the company’s Class A Common Stock on May 26, 2026. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan.

The sales occurred in three tranches: 3,507 shares at a weighted average price of $53.3237, 2,100 shares at $54.3733, and 300 shares at $55.2233. All reported holdings are direct, and no option exercises or derivative transactions are included in this filing.

Insider Trade Summary 10b5-1

Net Seller: 5,907 shares

Net Sell 3 txns

Insider Budge James

Role Chief Financial Officer

Sold 5,907 shs ($318K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	3,507	$53.3237	$187K
Sale	Class A Common Stock	2,100	$54.3733	$114K
Sale	Class A Common Stock	300	$55.2233	$17K

Holdings After Transaction: Class A Common Stock — 445,386 shares (Direct)

Footnotes (4)

1. F1. The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025.
2. F2. Represents the weighted average sale price. The lowest price at which shares were sold was $52.88 and the highest price at which shares were sold was $53.85. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
3. F3. Represents the weighted average sale price. The lowest price at which shares were sold was $53.88 and the highest price at which shares were sold was $54.86. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
4. F4. Represents the weighted average sale price. The lowest price at which shares were sold was $55.05 and the highest price at which shares were sold was $55.36. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

Key Figures

Total shares sold: 5,907 shares Tranche 1 sale: 3,507 shares at $53.3237 Tranche 2 sale: 2,100 shares at $54.3733 +2 more

5 metrics

Total shares sold 5,907 shares Net open-market sales by CFO on May 26, 2026

Tranche 1 sale 3,507 shares at $53.3237 Class A Common Stock, open-market sale

Tranche 2 sale 2,100 shares at $54.3733 Class A Common Stock, open-market sale

Tranche 3 sale 300 shares at $55.2233 Class A Common Stock, open-market sale

Net buy/sell direction Net sell of 5,907 shares All transactions in this Form 4

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, open-market sale, Class A Common Stock

4 terms

Rule 10b5-1 trading plan financial

"The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"Represents the weighted average sale price. The lowest price at which shares were sold was $52.88 and the highest price at which shares were sold was $53.85."

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Class A Common Stock financial

"security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Hinge Health (HNGE) disclose for its CFO?

Hinge Health reported that CFO James Budge sold 5,907 shares of Class A Common Stock in open-market transactions. The sales occurred on May 26, 2026, across three price ranges, and were made under a pre-arranged Rule 10b5-1 trading plan.

At what prices did the Hinge Health (HNGE) CFO sell his shares?

The CFO’s sales were at weighted average prices of $53.3237, $54.3733, and $55.2233 per share. Footnotes state each line reflects a range, with detailed per-price breakdowns available upon request from the company, the SEC staff, or shareholders.

How many Hinge Health (HNGE) shares did the CFO sell in total?

CFO James Budge sold a total of 5,907 shares of Hinge Health Class A Common Stock. The filing shows three transactions: 3,507 shares, 2,100 shares, and 300 shares, all reported as open-market sales of non-derivative equity on May 26, 2026.

Was the Hinge Health (HNGE) CFO trade made under a Rule 10b5-1 plan?

Yes. A footnote explains the reported sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2025. Such plans are pre-arranged trading programs that schedule future stock transactions in advance.

Did the Hinge Health (HNGE) Form 4 include any option exercises or derivatives?

No. The filing reports only non-derivative transactions in Class A Common Stock and shows zero derivative transactions in the derivative summary. There were no option exercises, conversions, gifts, or tax-withholding dispositions disclosed in this Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/27/2026 - 07:16 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Budge James

(Last) (First) (Middle)

C/O HINGE HEALTH, INC.

455 MARKET STREET, SUITE 700

(Street)

SAN FRANCISCO CALIFORNIA 94105

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hinge Health, Inc. [ HNGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	05/26/2026		S(1)		3,507	D	$53.3237(2)	447,786	D
Class A Common Stock	05/26/2026		S(1)		2,100	D	$54.3733(3)	445,686	D
Class A Common Stock	05/26/2026		S(1)		300	D	$55.2233(4)	445,386	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $52.88 and the highest price at which shares were sold was $53.85. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

3. Represents the weighted average sale price. The lowest price at which shares were sold was $53.88 and the highest price at which shares were sold was $54.86. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

4. Represents the weighted average sale price. The lowest price at which shares were sold was $55.05 and the highest price at which shares were sold was $55.36. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

	/s/ James Budge	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)